Matinas Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on August 9, 2023. The filing serves to announce the Company's financial results for the quarter ended June 30, 2023, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained within the press release (Exhibit 99.1) and are not included in the body of this Form 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in this document. The filing acts solely as a notification of the release of quarterly results.
Guidance, Outlook, and Risks
The text does not provide specific guidance, outlook, management commentary, or risk factors. It includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2023) for actual revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of any debt obligations or financing activities not detailed in this summary.